Aurobindo Pharma moves up on receiving OAI from USFDA for oral solids manufacturing facility

31 Jan 2020 Evaluate

Aurobindo Pharma is currently trading at Rs. 482.35, up by 2.05 points or 0.43% from its previous closing of Rs. 480.30 on the BSE.

The scrip opened at Rs. 483.90 and has touched a high and low of Rs. 486.75 and Rs. 477.25 respectively. So far 39501 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 389.70 on 14-Nov-2019.

Last one week high and low of the scrip stood at Rs. 517.50 and Rs. 466.75 respectively. The current market cap of the company is Rs. 28125.05 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.60% and 13.53% respectively.

Aurobindo Pharma has received a letter from US Food and Drug Administration (USFDA) classifying the inspection conducted at Unit VII, an oral solids formulation manufacturing facility as Official Action Indicated (OAI). The inspection was conducted on October 7 to 11, 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1160.00 1.50 (0.13%)
16-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.20
Dr. Reddys Lab 5820.00
Cipla 1423.85
Zydus Lifesciences 1008.15
Lupin 1659.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.